DK2461812T3 - Præparat til behandling af cystisk fibrose - Google Patents

Præparat til behandling af cystisk fibrose

Info

Publication number
DK2461812T3
DK2461812T3 DK10739941.2T DK10739941T DK2461812T3 DK 2461812 T3 DK2461812 T3 DK 2461812T3 DK 10739941 T DK10739941 T DK 10739941T DK 2461812 T3 DK2461812 T3 DK 2461812T3
Authority
DK
Denmark
Prior art keywords
preparation
treatment
cystic fibrosis
cystic
fibrosis
Prior art date
Application number
DK10739941.2T
Other languages
English (en)
Inventor
Michael Freissmuth
Xaver Koenig
Christina Gloeckel
Original Assignee
Scipharm Sarl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scipharm Sarl filed Critical Scipharm Sarl
Application granted granted Critical
Publication of DK2461812T3 publication Critical patent/DK2461812T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK10739941.2T 2009-08-07 2010-08-05 Præparat til behandling af cystisk fibrose DK2461812T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09167491 2009-08-07
PCT/EP2010/061428 WO2011015630A1 (en) 2009-08-07 2010-08-05 Composition for the treatment of cystic fibrosis

Publications (1)

Publication Number Publication Date
DK2461812T3 true DK2461812T3 (da) 2014-04-07

Family

ID=41382119

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10739941.2T DK2461812T3 (da) 2009-08-07 2010-08-05 Præparat til behandling af cystisk fibrose

Country Status (25)

Country Link
US (2) US20120184622A1 (da)
EP (1) EP2461812B1 (da)
JP (1) JP5877787B2 (da)
KR (1) KR101729800B1 (da)
CN (1) CN102548559B (da)
AU (1) AU2010280684B2 (da)
BR (1) BR112012002578B8 (da)
CA (1) CA2770066C (da)
CL (1) CL2012000319A1 (da)
CY (1) CY1114983T1 (da)
DK (1) DK2461812T3 (da)
EA (1) EA023720B1 (da)
ES (1) ES2451790T3 (da)
GT (1) GT201200038A (da)
HN (1) HN2012000297A (da)
HR (1) HRP20140277T1 (da)
IL (1) IL217899B (da)
PL (1) PL2461812T3 (da)
PT (1) PT2461812E (da)
RS (1) RS53234B (da)
SG (1) SG178315A1 (da)
SI (1) SI2461812T1 (da)
SM (1) SMT201400057B (da)
WO (1) WO2011015630A1 (da)
ZA (1) ZA201200790B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY157166A (en) 2009-06-12 2016-05-13 Mankind Corp Diketopiperazine microparticles with defined specific surface areas
ES2693622T3 (es) 2011-01-13 2018-12-13 SciPharm S.à r.l. Método para mejorar el injerto de células madre hematopoyéticas
SI2672957T1 (sl) 2011-02-07 2017-03-31 Scipharm Sarl Nova sestava za zdravljenje cistične fibroze
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2927844T3 (es) 2013-01-11 2022-11-11 Corsair Pharma Inc Profármacos de treprostinil
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR102465025B1 (ko) 2013-07-18 2022-11-09 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
SI3060041T1 (sl) 2013-10-25 2021-04-30 Insmed Incorporated Spojine prostaciklina
EP3904326A1 (en) 2014-11-18 2021-11-03 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US10898494B2 (en) 2016-05-05 2021-01-26 Liquidia Technologies, Inc. Dry powder treprostinil for the treatment of pulmonary hypertension
CA3038276A1 (en) 2016-09-26 2018-03-29 United Therapeutics Corporation Treprostinil prodrugs
CN114072136B (zh) 2019-04-29 2024-11-29 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
WO2021041320A1 (en) 2019-08-23 2021-03-04 United Therapeutics Corporation Treprostinil prodrugs
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
US11793780B2 (en) 2020-06-09 2023-10-24 United Therapeutics Corporation Prodrugs of treprosiinil
KR20250133451A (ko) 2020-12-14 2025-09-05 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
AU2022229367A1 (en) 2021-03-03 2023-09-14 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6310898A (en) * 1997-03-14 1998-10-12 Toray Industries, Inc. Sustained-release prostaglandin i derivative preparation
US20010006979A1 (en) * 1998-07-08 2001-07-05 Richard Stratton Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives
AU2002330747B2 (en) * 2001-08-31 2007-07-19 Sucampo Ag Prostaglandin analogs as chloride channel opener
US7550133B2 (en) * 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
ES2670872T3 (es) * 2003-05-22 2018-06-01 United Therapeutics Corporation Polimorfo de una sal de dietanolamina de treprostinil
US20040265238A1 (en) * 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
US20080096915A1 (en) * 2005-01-13 2008-04-24 Greenberg Traurig LLP Compositions for the treatment of metabolic disorders
US7893050B2 (en) * 2005-10-26 2011-02-22 Asahi Kasei Pharma Corporation Fasudil in combination therapies for the treatment of pulmonary arterial hypertension
WO2007092343A2 (en) * 2006-02-03 2007-08-16 Scidose Llc Novel epoprostenol formulation and method of making thereof
US20080280986A1 (en) * 2007-02-09 2008-11-13 United Therapeutics Corporation Treprostinil treatment for interstitial lung disease and asthma

Also Published As

Publication number Publication date
SI2461812T1 (sl) 2014-05-30
HRP20140277T1 (hr) 2014-04-25
EA023720B1 (ru) 2016-07-29
PL2461812T3 (pl) 2014-12-31
BR112012002578B1 (pt) 2021-01-12
GT201200038A (es) 2015-01-16
CN102548559A (zh) 2012-07-04
RS53234B (sr) 2014-08-29
JP2013501032A (ja) 2013-01-10
US10086001B2 (en) 2018-10-02
BR112012002578B8 (pt) 2021-05-25
US20160175319A1 (en) 2016-06-23
WO2011015630A1 (en) 2011-02-10
US20120184622A1 (en) 2012-07-19
HN2012000297A (es) 2015-05-18
EP2461812A1 (en) 2012-06-13
ZA201200790B (en) 2013-05-29
AU2010280684B2 (en) 2016-07-28
HK1165293A1 (en) 2012-10-05
KR101729800B1 (ko) 2017-04-24
CN102548559B (zh) 2013-12-25
AU2010280684A1 (en) 2012-02-23
EP2461812B1 (en) 2014-01-01
IL217899B (en) 2018-05-31
CA2770066C (en) 2018-10-23
KR20120056819A (ko) 2012-06-04
EA201200253A1 (ru) 2012-07-30
CL2012000319A1 (es) 2012-09-14
BR112012002578A2 (pt) 2016-03-15
CY1114983T1 (el) 2016-12-14
SG178315A1 (en) 2012-03-29
PT2461812E (pt) 2014-04-07
ES2451790T3 (es) 2014-03-28
IL217899A0 (en) 2012-03-29
JP5877787B2 (ja) 2016-03-08
SMT201400057B (it) 2014-07-07
CA2770066A1 (en) 2011-02-10

Similar Documents

Publication Publication Date Title
DK3192520T3 (da) Terapeutiske midler til reducering af niveauerne af parathyreoideahormon
SMT201400057B (it) Composizione per il trattamento della fibrosi cistica
PL2386171T3 (pl) Dostosowanie parametrów przekazania
DK2808024T3 (da) Bifidobakterier til behandling af kongestiv hjerteinsufficiens
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2672957T3 (da) Hidtil ukendt sammensætning til behandling af cystisk fibrose
DK2451482T3 (da) Kombinationsterapi til behandlingen af diabetes
DK2473170T3 (da) Anvendelse af aerosoliseret levofloxacin til behandling af cystisk fibrose
DK2382232T3 (da) Fremgangsmåde til fremstilling af bivalirudin
DK2627656T3 (da) Fremgangsmåde til fremstilling af dihydropteridinon og intermediater deraf
BRPI1010516A2 (pt) Métodos de tratamento de edema relacionados à isquemia-reperfusão
DK2462108T3 (da) Fremgangsmåde til fremstilling af pyrazolcarboxylsyreamider
DK2516359T3 (da) Fremgangsmåde til fremstilling af ethylbenzen
BRPI1016153A2 (pt) Massa instantânea integral
DK2493860T3 (da) Fremgangsmåde til fremstilling af 4-sulfinylpyrazolderivater
DK2151429T3 (da) Fremgangsmåde til fremstilling af agomelatin
DK2655360T3 (da) Fremgangsmåde til fremstilling af n-sulfonylsubstituerede oxindoler
DK2310017T3 (da) Nifurtimox til behandling af sygdomme fremkaldt af trichomonadida
EP2309854A4 (en) ACCELERATED THERAPY:
EP2266520A4 (en) Massage machine
EP2490704A4 (en) THERAPEUTIC COMPOSITION
DE112010001392A5 (de) Vibrator
DK2408764T3 (da) Ny fremgangsmåde til fremstilling af enaminocarbonyl-forbindelser
NO20085335L (no) Malingsavrasper
TH0801005787A (th) กระบวนการสำหรับการเตรียมของเบทาอีน